P/E ratio for MannKind Corp (MNKD)
P/E ratio as of April 2024 (TTM): -22.1
According to MannKind Corp's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -22.0526. At the end of 2022 the company had a P/E ratio of -15.5.
P/E ratio history for MannKind Corp from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -15.5 | 13.5% |
| 2021 | -13.7 | 9.08% |
| 2020 | -12.5 | 162.05% |
| 2019 | -4.78 | 174.95% |
| 2018 | -1.74 | -16.86% |
| 2017 | -2.09 | -182.3% |
| 2016 | 2.54 | -255.88% |
| 2015 | -1.63 | -84.08% |
| 2014 | -10.2 | 25.97% |
| 2013 | -8.13 | 234.15% |
| 2012 | -2.43 | 28.39% |
| 2011 | -1.89 | -64.75% |
| 2010 | -5.37 | 26.97% |
| 2009 | -4.23 | 266.43% |
| 2008 | -1.15 | -46.9% |
| 2007 | -2.17 | -40.39% |
| 2006 | -3.65 | -6.69% |
| 2005 | -3.91 | -8.65% |
| 2004 | -4.28 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 14.1 | -164.05% | 🇺🇸 USA |
 Novo Nordisk NVO | 44.2 | -300.33% | 🇩🇰 Denmark |
 Eli Lilly LLY | 135 | -711.54% | 🇺🇸 USA |
 Merck MRK | 69.7 | -416.13% | 🇺🇸 USA |
 Halozyme Therapeutics HALO | 22.5 | -201.95% | 🇺🇸 USA |
 Nektar Therapeutics
NKTR | -0.8466 | -96.16% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.